Company Profile
Cell Valley Group was founded by a team of passionate, visionary Chinese scientists with backgrounds in the United States and Hong Kong. Its founding members are alumni of world-renowned universities, including Harvard University, Cornell University, Columbia University, and the University of California, San Diego—bringing exceptional research capabilities and a global perspective to the group. The cutting-edge research concepts, profound academic foundations, and strong innovation capabilities fostered by these top-tier institutions have laid a solid groundwork for Cell Valley Group’s development.
Currently, Cell Valley Group has established a cell production center in Pingshan District, Shenzhen; a viral vector production center in Torch Development Zone, Zhongshan; and a northern R&D center in Daxing District, Beijing. The group comprises five wholly owned subsidiaries:
Shenzhen Cell Valley, Shenzhen-Hong Kong Cell Valley, Guangzhou Cell Valley, Guangdong Junhou Biotechnology, and Beijing Jingshen Cell Valley—forging an industrial layout that spans South and North China. It has built over 10,000 square meters of GMP-compliant production workshops and high-standard R&D laboratories, along with two internationally compliant P2-level biosafety laboratories in Shenzhen and Zhongshan. Its core technological advantages include: China’s first clinical-grade retroviral vector GMP industrial production line (completed in 2020), a library of more than 100 clinical-grade
viral vectors, the internationally advanced eVLP-KOKI gene editing and delivery system, and China’s first GMP-grade natural killer (NK) cell and γδT cell exosome production line capable of large-scale manufacturing—solidifying its position at the forefront of the industry.
On September 7, 2024, the Ministry of Commerce, the National Health Commission, and the National Medical Products Administration jointly issued the
Notice on Carrying out Pilot Work on Expanding Opening-up in the Medical Field, marking the first time that foreign-invested enterprises in free trade zones (including Guangdong) are permitted to engage in the research and application of human stem cell, gene diagnosis, and treatment-related technologies. As the first overseas (Hong Kong)-invested enterprise to benefit from this policy, Cell Valley Group officially established Shenzhen-Hong Kong Cell Valley (Shenzhen) Medical Technology Co., Ltd. in Shenzhen’s Qianhai Free Trade Zone in February 2025, with a registered capital of 100 million RMB. Over 20% of its employees are from Hong Kong and the United States. Serving as the group’s headquarters for international business and medical services, Shenzhen-Hong Kong Cell Valley targets markets in the Guangdong-Hong Kong-Macao Greater Bay Area, Southeast Asia, Europe, and the Americas. It focuses on high-end cell and gene therapy solutions while actively expanding into consumer healthcare sectors such as wellness, medical aesthetics, and anti-aging—creating an innovative business model driven by both “medical services + consumer healthcare.” Leveraging the group’s core technologies and processes in clinical-grade viral vector preparation, gene editing and delivery systems, stem cell and immune cell platforms, and large-scale industrial production of various
exosomes, Shenzhen-Hong Kong Cell Valley is committed to building a world-leading one-stop service platform for cell and gene therapy and health management.
Shenzhen Cell Valley, the group’s production and R&D headquarters, has been recognized with numerous honors, including: Shenzhen Biomedical Industry Major Public Service Platform; National Engineering Research Center for Key Generic Technologies of the Cell Industry – Viral Vector Shared Technology Research Platform; Achievement Industrialization Base of the Shenzhen High-Tech Zone Development Special Plan Innovation Platform; Vice President Unit of the China Food and Drug Enterprise Quality and Safety Promotion Association; Recipient of Shenzhen Medical Research Special Fund Support; Vice Chairman Unit of the Shenzhen Biomedical Industry-Education Alliance; 2023 Class D High-Growth Enterprise under the “Julong Leading Talent” Program in Pingshan District’s Biomedical Field; Technology-Based Small and Medium-Sized Enterprise; Innovative Small and Medium-Sized Enterprise; and Shenzhen Pingshan District University Student Internship Base. It is also among Shenzhen’s newly announced “20+8” strategic emerging industry projects. In 2022,
Shenzhen Cell Valley’s project—“One-Stop Cell and Gene Therapy CRO/CDMO Service Platform – South China Cell Factory”—was approved as a key project by the Shenzhen Municipal Government.
Shenzhen Cell Valley has built a multi-functional integrated production and service platform covering a total area of 8,000 square meters, including 4,000 square meters of “C+A, B+A” clean workshops. This platform is equipped with GMP-compliant industrial production lines for retroviral vectors and cell products, GLP-compliant process development and analysis laboratories, and office spaces.
Scan to follow our latest news 
